| Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.J Clin Oncol | PMID 37058687PMC10414727 | 2023-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.JAMA Dermatol | PMID 37074705PMC10116386 | 2023-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.J Clin Oncol | PMID 37235976无 PMCID | 2023-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med | PMID 37256976PMC11335038 | 2023-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.Thorax | PMID 35793833PMC10314034 | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An analysis of feasibility of robotic colectomy: post hoc analysis of a phase III randomised controlled trial.J Robot Surg | PMID 36525149无 PMCID | 2023-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials.J Rheumatol | PMID 36725056无 PMCID | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Traditional Vietnamese medicine Kovir capsule for non-severe COVID-19 patients: A phase III double-blind randomized controlled trial.Phytother Res | PMID 36751127无 PMCID | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.Diabetes Obes Metab | PMID 36782093无 PMCID | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Accurate tumor segmentation and treatment outcome prediction with DeepTOP.Radiother Oncol | PMID 36813177无 PMCID | 2023-Jun | 0.95 | The study uses data from a phase III RCT to develop and validate a deep learning tool for tumor segmentation and prediction of pathological complete response. It does not report time-to-event efficacy endpoints (OS, PFS, DFS, etc.) or Kaplan-Meier/HR results. Therefore, it is not eligible for the Kaplan-Meier digitization cohort. | 待处理 |
| Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation.Gastroenterology | PMID 36822371无 PMCID | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF.J Oncol Pharm Pract | PMID 36823960无 PMCID | 2023-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial.Am J Hematol | PMID 36877527无 PMCID | 2023-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.Eur Urol | PMID 36894488无 PMCID | 2023-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.Breast Cancer Res Treat | PMID 36947277PMC10175450 | 2023-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity.Clin Oncol (R Coll Radiol) | PMID 37012180PMC10186116 | 2023-Jun | 0.95 | The record describes a sub-study analysis from the SECRAB trial focusing on quality of life, cosmesis, and chemotherapy dose intensity. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The main trial efficacy (local recurrence) is mentioned in the abstract but is not the focus of this specific report, which is a secondary analysis of non-efficacy outcomes. | 待处理 |
| Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes.Clin Pharmacol Ther | PMID 37017631无 PMCID | 2023-Jun | 0.90 | The study is a Phase III randomized trial of molnupiravir for COVID-19, not for human malignant neoplasm. It does not have a primary/key secondary time-to-event efficacy endpoint like OS or PFS; outcomes are based on logistic regression of hospitalization (binary). | 待处理 |
| Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.Cancer Chemother Pharmacol | PMID 37093266PMC10124690 | 2023-Jun | 0.85 | The study is an original Phase III randomized controlled trial of a drug-containing intervention (biosimilar rituximab) for human oncology (diffuse large B-cell lymphoma). However, the primary efficacy endpoint is objective response rate (ORR), which is not a time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). Therefore, it does not meet the criterion for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.United European Gastroenterol J | PMID 37139642PMC10256988 | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.Lancet Diabetes Endocrinol | PMID 37148899无 PMCID | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet HIV | PMID 37167996PMC10280394 | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of HPV self-collection kits on cervical cancer screening uptake among under-screened women from low-income US backgrounds (MBMT-3): a phase 3, open-label, randomised controlled trial.Lancet Public Health | PMID 37182529PMC10283467 | 2023-Jun | 0.85 | The record describes a phase 3 randomized trial in the oncology domain (cervical cancer screening) and is an original primary result report. However, the intervention consists of mailed HPV self-collection kits and scheduling assistance, which are non-drug interventions. Furthermore, the primary efficacy endpoint is cervical cancer screening uptake (a binary proportion), not a time-to-event endpoint such as OS, PFS, DFS, etc. Therefore, it fails the required criteria for drug intervention and time-to-event endpoint. | 待处理 |
| Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 37182538无 PMCID | 2023-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.Lancet Neurol | PMID 37210098无 PMCID | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Neurol | PMID 37210099无 PMCID | 2023-Jun | 0.90 | The record describes a Phase 3 randomized controlled trial of valbenazine for Huntington's disease chorea, which is not a malignant neoplasm. The primary endpoint is a change in a clinical rating scale (UHDRS TMC score), not a time-to-event efficacy endpoint such as overall survival or progression-free survival. Therefore, it does not meet the oncology or time-to-event criteria required for inclusion. | 待处理 |
| Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial.Heart Rhythm | PMID 37245897无 PMCID | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 37269841PMC10641914 | 2023-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.Nat Med | PMID 37291210PMC10287558 | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.Nat Cancer | PMID 37322367无 PMCID | 2023-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial.BMJ Open Diabetes Res Care | PMID 37328272PMC10277051 | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.J Immunother Cancer | PMID 37399357PMC10314681 | 2023-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION).Endocrinol Metab (Seoul) | PMID 37408283PMC10323160 | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.PLoS Negl Trop Dis | PMID 37352322PMC10325040 | 2023-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study.Trials | PMID 37248494PMC10226221 | 2023-May-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.Lancet | PMID 37086745无 PMCID | 2023-May-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.Lancet | PMID 37116524无 PMCID | 2023-May-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hydrocortisone in Severe Community-Acquired Pneumonia.N Engl J Med | PMID 36942789无 PMCID | 2023-May-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.N Engl J Med | PMID 37224196PMC10627475 | 2023-May-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med | PMID 37224198无 PMCID | 2023-May-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.Jpn J Infect Dis | PMID 36724939无 PMCID | 2023-May-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.Br J Dermatol | PMID 36967713无 PMCID | 2023-May-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.Br J Dermatol | PMID 36994947无 PMCID | 2023-May-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma.Blood Adv | PMID 36574241PMC10196991 | 2023-May-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.Vaccine | PMID 37127523PMC10148668 | 2023-May-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.Chin Med J (Engl) | PMID 37010251PMC10278759 | 2023-May-20 | 0.45 | The trial is a randomized Phase III oncology study with a drug intervention, but its primary efficacy endpoint is the percentage of patients achieving a pharmacodynamic endpoint (testosterone suppression ≤50 ng/dL) and its cumulative probability over a fixed time period (day 29 to 85). This is not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier curve or hazard ratio for such an endpoint is described. | 待处理 |
| Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.Lancet | PMID 37068504无 PMCID | 2023-May-20 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.J Clin Oncol | PMID 37196429无 PMCID | 2023-May-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg®) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial.Medicine (Baltimore) | PMID 37335745PMC10194448 | 2023-May-19 | 0.80 | This is a Phase III randomized trial in human oncology patients with a drug intervention (pegteograstim). However, the primary endpoint is the duration of grade 4 neutropenia, which is a safety/toxicity measure, not a time-to-event efficacy endpoint such as OS, PFS, DFS, or TTP. The study does not report Kaplan-Meier curves or hazard ratios for a survival or tumor progression outcome. Therefore, it does not meet the key criterion of having a primary or key secondary time-to-event efficacy endpoint. | 待处理 |
| Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial.J Patient Rep Outcomes | PMID 37195456PMC10189706 | 2023-May-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).Vaccine | PMID 37105892无 PMCID | 2023-May-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |